文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT与平均肺剂量模型预测III期非小细胞肺癌放化疗联合免疫治疗患者的早期放射性肺炎

An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
PubMed 文献 · J Nucl Med · 2024-04-01

本研究分析了160例接受同步放化疗联合巩固免疫治疗的III期非小细胞肺癌患者,其中20例(13%)发生早期放射性肺炎。研究检验了3个已发表的含平均肺剂量(MLD)的放射性肺炎模型及治疗前18F-FDG PET/CT正常肺SUV特征,发现MLD单独及SUVP10、SUVP90、SUVmean均与早期放射性肺炎相关。联合MLD与SUVP90的最终模型在验证子集中泛化良好,在160例中重新拟合后较已发表的MLD单独模型表现改善(AUC 0.77 vs 0.72)。

要点

  • 160例III期非小细胞肺癌患者中20例(13%)发生早期放射性肺炎。
  • MLD单独预测早期放射性肺炎AUC 0.72,SUVP10、SUVP90、SUVmean的AUC为0.70-0.74。
  • 联合MLD与SUVP90的最终模型在验证子集中泛化,重新拟合后AUC 0.77优于MLD单独模型的0.72。

核心结论

  • 联合正常肺的MLD与治疗前18F-FDG PET/CT的SUVP90可高确定性地识别有早期放射性肺炎风险的患者。
  • 该改良模型可用于识别因早期放射性肺炎而提前中断免疫治疗的高风险患者,并可能允许采取干预措施以改善治疗结局。

研究设计与样本

  • 分析了160例接受同步放化疗联合巩固免疫治疗的III期非小细胞肺癌患者。
  • 检验了3个已发表的含MLD和患者特征的放射性肺炎模型,以及治疗前18F-FDG PET/CT正常肺SUV特征(SUVP10、SUVP90、SUVmax、SUVmean、最小SUV、SD)。
  • 队列随机按70%/30%拆分为推导集/内部验证集,两集早期放射性肺炎发生率相似。

主要发现

  • 20例(13%)患者发生早期放射性肺炎。
  • MLD单独预测早期放射性肺炎:AUC 0.72,P=0.02,Hosmer-Lemeshow检验pH=0.87。
  • SUVP10、SUVP90和SUVmean预测早期放射性肺炎:AUC 0.70-0.74,P=0.003-0.006,pH=0.67-0.70。
  • 联合MLD与SUVP90的模型在验证子集中泛化,被定为最终早期放射性肺炎模型:风险=1/[1+e^(-x)],x=-6.08+[0.17×MLD]+[1.63×SUVP90]。
  • 最终模型在160例中重新拟合后较已发表的MLD单独模型改善:AUC 0.77 vs 0.72,P=0.0001 vs 0.02,pH=0.65 vs 0.87。

关键数值与推荐

  • 最终早期放射性肺炎模型:风险=1/[1+e^(-x)],x=-6.08+[0.17×MLD]+[1.63×SUVP90]。
  • MLD单独模型预测早期放射性肺炎AUC 0.72(P=0.02,pH=0.87)。
  • 最终模型在160例中重新拟合AUC 0.77(P=0.0001,pH=0.65),已发表MLD单独模型AUC 0.72(P=0.02,pH=0.87)。

临床怎么用

  • 联合正常肺MLD与治疗前18F-FDG PET/CT SUVP90可识别早期放射性肺炎高风险患者。
  • 该模型可用于识别因早期放射性肺炎而提前中断免疫治疗的高风险患者,并可能允许采取干预措施以改善治疗结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiation pneumonitis (RP) that develops early (i.e., within 3 mo) (RPEarly) after completion of concurrent chemoradiation (cCRT) leads to treatment discontinuation and poorer survival for patients with stage III non-small cell lung cancer. Since no RPEarly risk model exists, we explored whether published RP models and pretreatment 18F-FDG PET/CT-derived features predict RPEarly Methods: One hundred sixty patients with stage III non-small cell lung cancer treated with cCRT and consolidative immunotherapy were analyzed for RPEarly Three published RP models that included the mean lung dose (MLD) and patient characteristics were examined. Pretreatment 18F-FDG PET/CT normal-lung SUV featured included the following: 10th percentile of SUV (SUVP10), 90th percentile of SUV (SUVP90), SUVmax, SUVmean, minimum SUV, and SD. Associations between models/features and RPEarly were assessed using area under the receiver-operating characteristic curve (AUC), P values, and the Hosmer-Lemeshow test (pHL). The cohort was randomly split, with similar RPEarly rates, into a 70%/30% derivation/internal validation subset. Results: Twenty (13%) patients developed RPEarly Predictors for RPEarly were MLD alone (AUC, 0.72; P = 0.02; pHL, 0.87), SUVP10, SUVP90, and SUVmean (AUC, 0.70-0.74; P = 0.003-0.006; pHL, 0.67-0.70). The combined MLD and SUVP90 model generalized in the validation subset and was deemed the final RPEarly model (RPEarly risk = 1/[1+e(- x )]; x = -6.08 + [0.17 × MLD] + [1.63 × SUVP90]). The final model refitted in the 160 patients indicated improvement over the published MLD-alone model (AUC, 0.77 vs. 0.72; P = 0.0001 vs. 0.02; pHL, 0.65 vs. 0.87). Conclusion: Patients at risk for RPEarly can be detected with high certainty by combining the normal lung's MLD and pretreatment 18F-FDG PET/CT SUVP90 This refined model can be used to identify patients at an elevated risk for premature immunotherapy discontinuation due to RPEarly and could allow for interventions to improve treatment outcomes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thor M, Lee C, Sun L, et al. An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy. J Nucl Med. 2024. PMID: 38485270. doi:10.2967/jnumed.123.266965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。